CR20160444A - Proteínas de fusión uti - Google Patents

Proteínas de fusión uti

Info

Publication number
CR20160444A
CR20160444A CR20160444A CR20160444A CR20160444A CR 20160444 A CR20160444 A CR 20160444A CR 20160444 A CR20160444 A CR 20160444A CR 20160444 A CR20160444 A CR 20160444A CR 20160444 A CR20160444 A CR 20160444A
Authority
CR
Costa Rica
Prior art keywords
fusion proteins
uti fusion
uti
produce
methods
Prior art date
Application number
CR20160444A
Other languages
English (en)
Inventor
Aaron Chamberlain
Qiang Liu
Original Assignee
Takeda Gmbh
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Gmbh, Takeda Pharmaceuticals Co filed Critical Takeda Gmbh
Publication of CR20160444A publication Critical patent/CR20160444A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La presente invención provee proteínas de fusión UTI, secuencias de ADN para producir las mismas, y composiciones farmacéuticas y métodos para usar las mismas.
CR20160444A 2014-02-24 2015-02-23 Proteínas de fusión uti CR20160444A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461943617P 2014-02-24 2014-02-24
PCT/US2015/017152 WO2015127391A1 (en) 2014-02-24 2015-02-23 Uti fusion proteins

Publications (1)

Publication Number Publication Date
CR20160444A true CR20160444A (es) 2017-04-21

Family

ID=52629709

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20160444A CR20160444A (es) 2014-02-24 2015-02-23 Proteínas de fusión uti

Country Status (37)

Country Link
US (4) US9856310B2 (es)
EP (2) EP3110434B1 (es)
JP (4) JP6574431B2 (es)
KR (2) KR20220151005A (es)
CN (2) CN110092837B (es)
AR (1) AR101597A1 (es)
AU (4) AU2015218704B2 (es)
BR (1) BR112016019390B1 (es)
CA (2) CA3178241A1 (es)
CL (1) CL2016002136A1 (es)
CR (1) CR20160444A (es)
CY (1) CY1120997T1 (es)
DK (1) DK3110434T3 (es)
DO (1) DOP2016000202A (es)
EA (2) EA202091567A1 (es)
EC (1) ECSP16076535A (es)
ES (1) ES2700149T3 (es)
GE (1) GEP20196970B (es)
HR (1) HRP20182029T1 (es)
IL (1) IL247321B (es)
JO (1) JO3729B1 (es)
LT (1) LT3110434T (es)
MA (1) MA39347B2 (es)
MX (2) MX2016010950A (es)
MY (1) MY178774A (es)
NZ (3) NZ760789A (es)
PE (1) PE20170257A1 (es)
PH (1) PH12016501629A1 (es)
PL (1) PL3110434T3 (es)
PT (1) PT3110434T (es)
RS (1) RS58285B1 (es)
SG (2) SG10201708400QA (es)
SI (1) SI3110434T1 (es)
TW (1) TWI694084B (es)
UA (1) UA118866C2 (es)
WO (1) WO2015127391A1 (es)
ZA (1) ZA201606327B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015218704B2 (en) * 2014-02-24 2019-05-02 Takeda Gmbh UTI fusion proteins
AU2018281306A1 (en) * 2017-06-07 2020-01-16 Spark Therapeutics, Inc. Enhancing agents for improved cell transfection and/or rAAV vector production
WO2020106881A1 (en) * 2018-11-20 2020-05-28 Diamedica Inc. Modified ulinastatin polypeptides
JP2021050161A (ja) 2019-09-25 2021-04-01 武田薬品工業株式会社 複素環化合物及びその用途
JP2021080177A (ja) 2019-11-14 2021-05-27 武田薬品工業株式会社 複素環化合物及びその用途
BR112022017718A2 (pt) 2020-03-05 2022-11-16 Diamedica Usa Inc Polipeptídeos de ulinastatina

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5663143A (en) * 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
EP0401508B1 (de) 1989-05-13 1994-11-23 Bayer Ag Proteinaseninhibitoren, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel
JPH0584083A (ja) 1990-11-13 1993-04-06 Mochida Pharmaceut Co Ltd 新規ポリペプチド、それをコードする新規ｄｎａ、新規ポリペプチドの製造方法、新規医薬組成物、および新規酵素阻害方法
JP2769083B2 (ja) 1993-02-22 1998-06-25 日清食品株式会社 エラスターゼ阻害活性を有する新規ペプチドおよびその製造方法
PT891426E (pt) 1996-03-11 2006-10-31 Bayer Corp Bicunina humana
DE19725014A1 (de) 1997-06-13 1998-12-17 Bayer Ag Aprotininvarianten mit verbesserten Eigenschaften und Bikunine von Aprotininvarianten
AU2005229457B2 (en) * 2004-03-30 2010-11-25 Glaxo Group Limited Immunoglobulins
CN101124248A (zh) 2004-08-11 2008-02-13 特鲁比昂药品公司 结合域融合蛋白
WO2006129849A1 (ja) * 2005-06-03 2006-12-07 Mochida Pharmaceutical Co., Ltd. 抗ｃｄ１４抗体融合蛋白質
SI1981519T1 (en) 2005-12-29 2018-05-31 Dyax Corp. INHIBITION PROTEAZE
HUE033438T2 (en) * 2008-09-26 2017-11-28 Ucb Biopharma Sprl Biological products
CN101721699B (zh) * 2008-10-13 2012-11-07 成都康弘生物科技有限公司 Vegf受体融合蛋白在制备治疗伴随vegf升高的炎症反应的药物中的应用
CN102580085B (zh) * 2008-10-13 2013-09-18 成都康弘生物科技有限公司 Vegf受体融合蛋白在制备治疗脓毒症药物中的应用
US20120052069A1 (en) * 2009-05-05 2012-03-01 Amgen Inc Fgf21 mutants and uses thereof
PL2704737T3 (pl) * 2011-04-29 2018-07-31 University Of Washington Terapeutyczne kompozycje nukleaz i sposoby
US8619331B2 (en) 2011-07-19 2013-12-31 Xerox Corporation Simulated paper texture using clear toner and glossmark on texture-less stock
BR112014013205A2 (pt) * 2011-12-01 2020-10-27 Protevobio, Inc. proteína de fusão, seu uso e seu método de produção, composição farmacêutica, ácido nucleico, e kit
US9809641B2 (en) * 2012-04-23 2017-11-07 Nrl Pharma, Inc. Lactoferrin fusion protein and method for preparation thereof
CN103044554B (zh) * 2012-05-14 2014-08-27 旭华（上海）生物研发中心有限公司 重组二聚化人尿胰蛋白酶抑制剂、其制备方法及其应用
JP2013253079A (ja) * 2012-05-14 2013-12-19 Xuhua (Shanghai) Biological Research & Development Center Co Ltd 生物学的に活性なヒト尿中トリプシンインヒビターのＦｃ融合タンパク質並びにその調製および使用
AU2015218704B2 (en) * 2014-02-24 2019-05-02 Takeda Gmbh UTI fusion proteins

Also Published As

Publication number Publication date
AU2021225156A1 (en) 2021-09-30
DK3110434T3 (en) 2019-01-14
AU2015218704B2 (en) 2019-05-02
AU2019204448B2 (en) 2021-06-10
MY178774A (en) 2020-10-20
KR20160141718A (ko) 2016-12-09
EA201691702A1 (ru) 2017-01-30
BR112016019390A2 (pt) 2017-10-24
EP3110434A1 (en) 2017-01-04
UA118866C2 (uk) 2019-03-25
TWI694084B (zh) 2020-05-21
US20180072795A1 (en) 2018-03-15
DOP2016000202A (es) 2016-12-15
US20200040062A1 (en) 2020-02-06
CL2016002136A1 (es) 2017-08-11
PH12016501629A1 (en) 2017-02-06
JP6938565B2 (ja) 2021-09-22
EP3443978A1 (en) 2019-02-20
SI3110434T1 (sl) 2019-02-28
MX2016010950A (es) 2017-04-25
JP2022002513A (ja) 2022-01-11
EA202091567A1 (ru) 2021-07-30
AU2021225156B2 (en) 2022-11-24
US20220127334A1 (en) 2022-04-28
TW201630931A (zh) 2016-09-01
NZ724196A (en) 2022-01-28
RS58285B1 (sr) 2019-03-29
CN106232135B (zh) 2019-12-10
NZ760008A (en) 2023-03-31
NZ760789A (en) 2023-03-31
CA2939639A1 (en) 2015-08-27
MX2019013124A (es) 2020-08-31
ZA201606327B (en) 2019-01-30
KR20220151005A (ko) 2022-11-11
AR101597A1 (es) 2016-12-28
CA3178241A1 (en) 2015-08-27
AU2023200875A1 (en) 2023-04-27
CN110092837A (zh) 2019-08-06
CN110092837B (zh) 2024-01-02
JP6574431B2 (ja) 2019-09-11
ECSP16076535A (es) 2017-08-31
EP3110434B1 (en) 2018-09-19
GEP20196970B (en) 2019-04-25
IL247321A0 (en) 2016-09-29
ES2700149T3 (es) 2019-02-14
PT3110434T (pt) 2018-12-19
JO3729B1 (ar) 2021-01-31
CA2939639C (en) 2023-01-24
PL3110434T3 (pl) 2019-01-31
MA39347A1 (fr) 2018-06-29
US9856310B2 (en) 2018-01-02
SG10201708400QA (en) 2017-11-29
SG11201606691QA (en) 2016-09-29
MA39347B2 (fr) 2020-05-29
CY1120997T1 (el) 2019-12-11
KR102461210B1 (ko) 2022-10-31
EA037256B1 (ru) 2021-02-26
US20160362475A1 (en) 2016-12-15
LT3110434T (lt) 2018-12-27
JP2017512058A (ja) 2017-05-18
US10351618B2 (en) 2019-07-16
AU2015218704A1 (en) 2016-09-22
HRP20182029T1 (hr) 2019-02-08
WO2015127391A1 (en) 2015-08-27
AU2019204448A1 (en) 2019-07-11
JP2019187427A (ja) 2019-10-31
JP2023123763A (ja) 2023-09-05
IL247321B (en) 2020-06-30
CN106232135A (zh) 2016-12-14
BR112016019390B1 (pt) 2023-11-14
PE20170257A1 (es) 2017-03-30

Similar Documents

Publication Publication Date Title
HK1253065A1 (zh) 靶向蛋白質的化合物、其組合物、方法和用途
DK4023755T3 (da) Kunstige nukleinsyremolekyler til forbedret proteinudtrykkelse
DK3292137T3 (da) Proteiner specifikke for cd137
DK3433368T3 (da) Transreplikerende rna
DK3341482T3 (da) Kunstige nukleinsyremolekyler
DK3604527T3 (da) Anvendelse af programmerbare dna-bindingsproteiner til at forbedre målrettet genommodifikation
EA201890493A1 (ru) РЕПРЕССОРЫ Htt И ИХ ПРИМЕНЕНИЕ
DK3234134T3 (da) Målrettet rna-redigering
AR101845A1 (es) Anticuerpos anti-her2 e inmunoconjugados
DK3292141T3 (da) Fusionsproteiner
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
DK3186233T3 (da) Prober til billeddannelse af huntingtin-protein
MX2016016886A (es) Anticuerpos anti-axl.
ECSP16076535A (es) Proteínas de fusión uti
DK3201336T3 (da) Fremgangsmåder til ekstrahering og oprensning af ikke-denaturerede proteiner
EA201790505A1 (ru) Соединение, нацеленое на ил-23а и фно-альфа, и его применение
DK3669886T3 (da) Knoglemorfogenetiske proteiner
DK3197277T3 (da) Prober til billeddannelse af huntingtin-protein
DK3164410T3 (da) Protein-indvinding
DK3608334T3 (da) Tatk-cdkl5-fusionsproteiner, sammensætninger, formuleringer og anvendelse deraf
BR112018009097A8 (pt) spodoptera frugiperda resistente a vip3a
IL265942A (en) A nucleotide sequence expressing an exosome anchor protein for use as a component
DK3149163T3 (da) Prohæmostatiske proteiner til behandling af blødning
UY36277A (es) Proteínas de fusión uti
TH1601001541A (th) โปรตีนฟิวชัน